Hypothesis

Chronic NAD+ depletion in aged tissues does not merely reflect increased consumption; it actively suppresses its own biosynthesis through a HIF‑1α‑driven epigenetic lock on the NAMPT promoter. This creates a self‑reinforcing low‑NAD+ state that limits cellular ambition by curtailing SIRT1 activity, mitochondrial biogenesis, and DNA repair capacity.

Mechanistic Reasoning

1. NAD+ fall → pseudohypoxia → HIF‑1α stabilization
   • Age‑related NAD+ loss reduces SIRT1 deacetylase activity, destabilizing VHL and allowing HIF‑1α accumulation even under normoxia2.
2. HIF‑1α recruits repressive chromatin complexes to NAMPT
   • HIF‑1α can bind hypoxia‑response elements (HREs) near the NAMPT promoter and, in conjunction with HDAC1/2 and DNMT3A, promotes histone deacetylation and DNA methylation4.
   • This epigenetic silencing lowers NAMPT transcription, further curtailing NAD+ salvage.1
3. Low NAD+ sustains HIF‑1α activity
   • Reduced NAD+ limits SIRT1‑mediated HIF‑1α deacetylation, prolonging its half‑life and reinforcing the loop.5
4. Consequences for cellular ambition
   • Persistent low NAD+ keeps SIRT1 below the threshold needed to activate PGC‑1α, FOXO, and DNA‑repair proteins, shifting metabolism toward glycolysis and limiting biosynthetic programs that underlie tissue maintenance.

Testable Predictions

• Prediction 1: Genetic ablation of Hif‑1α in aged mouse liver will increase NAMPT mRNA and protein levels, elevate NAD+ concentrations, and improve SIRT1 targets without altering CD38 or PARP activity.
• Prediction 2: Pharmacological inhibition of HIF‑1α (e.g., with PX‑478) in primary human fibroblasts from old donors will rescue NAMPT promoter acetylation (measured by ChIP‑qPCR for H3K27ac) and increase NAD+ salvage flux.
• Prediction 3: Forced HIF‑1α stabilization in young cells (via DMOG) will decrease NAMPT expression, lower NAD+, and induce a glycolytic shift, mimicking the aged metabolic phenotype.
• Prediction 4: Timed NAD+ precursor administration that restores circadian NAD+ oscillations will be more effective at reversing NAMPT promoter methylation than constant dosing, because rhythmic NAD+ peaks promote SIRT1‑dependent HIF‑1α deacetylation.

Experimental Approach

• Use liver‑specific Hif‑1α knockout mice (Hif‑1α^fl/fl; Alb‑Cre) aged to 24 mo; measure NAD+, NAMPT expression, SIRT1 activity, mitochondrial respiration, and markers of DNA repair.
• Treat primary human dermal fibroblasts from donors >65 yo with HIF‑1α inhibitor or siRNA; assess NAMPT promoter methylation (bisulfite sequencing), acetylation (ChIP), and NAD+ levels via LC‑MS.
• In young mouse embryonic fibroblasts, stabilize HIF‑1α with DMOG and quantify the same readouts.
• Compare effects of bolus NMN versus timed NMN dosing aligned to the active phase on NAMPT promoter epigenetic state in aged mice.

Falsifiability

If HIF‑1α loss or inhibition fails to raise NAMPT expression or NAD+ in aged tissues, or if forced HIF‑1α activation does not lower NAMPT/NAD+ in young cells, the proposed epigenetic feedback loop would be refuted. Likewise, if timed NAD+ supplementation shows no advantage over constant dosing in reversing NAMPT promoter methylation, the circadian component of the hypothesis would be unsupported.